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Abstract 
Since no randomized controlled trials have been conducted on the treatment of viral 
pneumonia by antivirals or immunomodulators in immunocompetent adults, a review of 
such anecdotal experience are needed for the more rational use of such agents. Case 
reports (single or case series) with details on their treatment and outcome in the English 
literature can be reviewed for pneumonia caused by human or avian influenza A virus (50 
patients), varicella-zoster virus (120), adenovirus (29), hantavirus (100) and SARS 
coronavirus (841). Even with steroid therapy alone, the mortality rate appeared to be 
lower when compared with conservative treatment for pneumonia caused by human 
influenza virus (12.5% vs 42.1%) and hantavirus (13.3% vs 63.4%).  Combination of an 
effective antiviral, acyclovir, with steroid in the treatment of varicella-zoster virus may be 
associated with a lower mortality than acyclovir alone (0% vs 10.3%). Combination of 
interferon alfacon-1 plus steroid, or lopinavir/ritonavir, ribavirin plus steroid were 
associated with a better outcome than ribavirin plus steroid (0% vs 2.3% vs 7.7% 
respectively).  Combination of lopinavir/ritonavir plus ribavirin significantly reduced the 
virus load of SARS-CoV in nasopharyngeal, serum, stool and urine specimens taken 
between day 10 and 15 after symptom onset when compared with the historical control 
group treated with ribavirin.  It appears that the combination of an effective antiviral and 
steroid was associated with a better outcome.  Randomized therapeutic trial should be 
conducted to ascertain the relative usefulness of antiviral alone or in combination with 
steroid. 
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Introduction 
The start of the new millennium is marked by two emerging infectious diseases coming 
from wild game food animals and poultry [1, 2]. Both SARS coronavirus (SARS-CoV) 
and avian influenza A H5N1 virus predominantly manifest as acute community acquired 
pneumonia with no response to empirical treatment by antibacterials covering typical and 
atypical agents [3-7].  SARS-CoV and avian influenza A H5N1 pneumonia are associated 
with significant mortality [7, 9]. Unfortunately, few prospective studies have been 
performed with documentation of the virus load changes during the course of illness for 
any respiratory viral pneumonia [8, 10]. The literature on the histological changes or 
pathogenesis of this condition is scarce. No randomized placebo-controlled treatment trial 
has ever been conducted.  Such lack of data was often attributed to the lack of rapid 
diagnostic tests and effective antivirals.  During the SARS outbreak, the empirical use of 
ribavirin and steroids were regarded as controversial [11-14]. Due to the explosive nature 
of the outbreak, randomized controlled trials on treatment could not be organized. 
Therefore, we attempt to review the literature on the rationale and strategy used in the 
treatment of acute community acquired viral pneumonia in immunocompetent adults. 
Virus load data and serological changes of acute respiratory viral pneumonia available in 
the literature, as well as from our SARS patients were included in this analysis.   
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Materials and methods  
All the case reports and series with clinical details involving medical therapy of viral 
pneumonia including SARS in patients aged 15 years or above were included in this 
review.  Patients with immunosuppressive conditions such as congenital or acquired 
immunodeficiencies, solid or marrow transplants, undergoing chemotherapy, and 
pregnancy were excluded. Where appropriate, the cited bibliographies were also 
retrieved for analysis.    
 
Preliminary review of these publications suggested that viral pneumonia caused by 
SARS-CoV constituted the majority of cases reported in the literature.  However, similar 
to other causes of viral pneumonia, little information on the virus load changes with 
respect to treatment was systematically reported. Therefore laboratory data from our 
cohort of 152 SARS patients who fulfilled the modified WHO definition were retrieved 
[5]. Virus load was measured on nasopharyngeal, serum, stool and urine specimens taken 
between day 10 and 15 after symptom onset.  Part of these data was previously reported 
[8, 10, 15, 16].  The virus load results were correlated with the specific antiviral regimens, 
namely ribavirin with and without lopinavir/ritonavir for SARS.  Serial quantitative RT-
PCRs and IgG titers of SARS-CoV were performed in 12 randomly selected patients who 
were treated with ribavirin and corticosteroid on day 5, 10, 15 and 20 after onset of 
symptoms.  To compare the serial virus load and antibody seroconversion with other 
respiratory virus infections, the English-language literature was searched to identify 
studies with detailed description of serial virus load and antibody titers during the course 
of infection.     
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Results 
In the literature review, there were 1997 and 322 English publications on human studies 
identified in PubMed when the combination of keywords “virus, pneumonia, treatment” 
and “SARS, treatment” were used on 11 January 2004 respectively.  Among the 1997 
publications, those related to HIV and AIDS patients (950), cancer and transplant patients 
(501), and vaccine and immunization topics (287), were excluded.  The remaining 259 
papers were retrieved and analyzed.    All the 322 SARS paper were retrieved and 
analyzed.  Subsequent PubMed search using the keywords of “influenza, pneumonia, 
treatment”, “respiratory syncytial virus, pneumonia, treatment”, “varicella, pneumonia, 
treatment”, “adenovirus, pneumonia, treatment”, and “hantavirus pulmonary syndrome, 
treatment” identified another 623, 267, 240, 146, and 83 papers respectively.   The cited 
bibliographies, if relevant, were also included in this review.  However, only 62 of these 
1940 papers contained clinical details and information on the medical treatment of viral 
pneumonia (44 papers) and SARS (18 papers) respectively. 
 
Of the 302 patients with non-SARS viral pneumonia in 44 case reports or series (table 1), 
their etiological diagnoses of human influenza A (n=38), avian influenza A H5N1 (n=12), 
varicella-zoster virus (VZV) (n=120), adenovirus (n=29), hantavirus (n=100), respiratory 
syncytial virus (RSV) (n=1), measles (n=1), and Epstein-Barr virus (EBV) (n=1), were 
documented by a combination of clinical features, radiographic changes, virological and 
serological tests [6, 7, 17-58].  Demographic details were mentioned in 171 (56.6%) 
patients.  There were 113 males and 58 females, with a median age of 31 years (ranged 
15-88).  The small number of patients suffering from pneumonia caused by RSV, measles, 
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EBV precluded any meaningful analysis or discussion [56-58].  As for the other agents, 
the overall mortality ranges from 9.2% (VZV), 20.7% (adenovirus), 31.6% (human 
influenza A), 49% (hantavirus) to 66.7% (avian influenza A H5N1).    
 
In the treatment of human influenza A infection, antiviral agents such as rimantadine (1 
patient), oseltamivir (5 patients), and a combination of rimantadine and oseltamivir had 
been used at a median of 3 days (ranged 1-7 days) after admission [20-23].  High dose 
corticosteroid without antiviral therapy was also attempted [20-22].  The dose of steroids 
ranged from hydrocortisone 250 mg ivi every 4 hours to methylprednisolone 500 mg ivi 
every 6 hours [21, 22].  Amantadine (4 patients), oseltamivir (3 patients), and a 
combination of antivirals and corticosteroid (3 patients) had also been used in the 
treatment of avian influenza A H5N1 [6, 7].  There was no apparent benefit since the 
antiviral agents were started at a median of 5 days (ranged 0-5 days) after admission.  
Corticosteroid such as intravenous methylprednisolone 1-2 mg/kg every 6 hourly for 3 to 
4 days had been given in 3 mechanically ventilated patients but 2 of them died of acute 
respiratory distress syndrome [6, 7]. 
 
As for VZV pneumonia, antiviral therapy including intravenous acyclovir 10-15 mg/kg 
every 8 hourly for 7 to 10 days was initiated in 66 out of 120 patients [26-38].   Two 
patients were treated with vidarabine before the widespread use of acyclovir [27, 38].  
Corticosteroids were combined with acyclovir in 17 patients [28, 29, 39-41].   The dosage 
and duration of steroids were quite variable (table 1) [29, 39-41].  Two patients received 
intravenous immunoglobulin (IVIG) together with intravenous acyclovir had a favorable 
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outcome [42, 43].  The mortality of patients who received acyclovir or vidarabine alone 
was 7 out of 68 (10.3%), whereas 4 patients managed with supportive care died. Only 1 
out of 25 patients died if intravenous acyclovir was initiated within 4 days of admission 
[27, 34, 35].  There was no death in patients treated with a combination of acyclovir and 
immunomodulators such as corticosteroid and IVIG [28, 29, 39-43]. 
 
As for adenoviral pneumonia, no antiviral was ever used for their treatment.  Two of 4 
(50%) patient receiving steroid died, which appeared to be higher than patients managed 
conservatively [21, 44-50].  The mortality for hantavirus pulmonary syndrome treated 
with intravenous ribavirin (47.7%) appeared to be only slightly lower than those treated 
conservatively (63.4%) [51-55].  The use of methylprednisolone was associated with a 
dramatic decrease of mortality to 13.3% [52, 53].   
 
Though there were 849 cases of SARS with treatment details reported in the literature, 
many of these patients were diagnosed according to the clinical criteria issued by WHO 
with or without laboratory confirmation (table 2) [3-5, 8, 10, 59-71].  One of the case 
series was not included because patients treated by different treatment regimens were 
aggregated together and could not be analyzed [72].  There were 349 males and 500 
females.  Except for 13 (1.5%) patients who were treated conservatively, antiviral therapy 
and / or immunomodulating therapy were given in all other patients.  Of 772 patients 
receiving specific antiviral therapy and / or immunomodulating therapy, 675 (87.4%) 
were treated with ribavirin containing regimens and 44 (5.7%) were treated with 
lopinavir/ritonavir containing regimens during the initial phase of the disease.  
 7
Cheng et al 
Immunomodulating therapy without antiviral agents was initiated in 53 of 772 (6.9%) 
patients.  Recombinant interferon alpha, corticosteroid, and a combination of interferon 
alfacon-1 and corticosteroid were used in 30 (3.9%), 14 (1.8%) and 9 (1.2%) cases 
respectively.  Of the 64 patients receiving treatment during clinical deterioration, 
ribavirin or oseltamivir, lopinavir/ritonavir, and convalescent plasma were given as 
rescue medical therapy in 32 (50%), 31 (48.4%), and 1 (1.6%) respectively.  High dose 
pulse methylprednisolone was used during clinical deterioration such as oxygen 
desaturation, worsening of radiographic infiltrates in the chest, recurrent fever without 
evidence of nosocomial sepsis in some reports.  However, the number of patients 
requiring pulse steroids was not mentioned in most of them [5, 8, 10, 59-62].  
Furthermore, intravenous immunoglobulin, thymic peptides, and recombinant human 
thymus proteins were used in some patients but the clinical details were not sufficient for 
any meaningful analysis [61].  The overall mortality was 7.7% in these 849 SARS cases.  
No obvious difference was noted irrespective of whether the patients were treated by 
ribavirin with or without corticosteroids, corticosteroids alone, or recombinant interferon-
alpha given on admission or during deterioration.  However, the mortality is only 2.3% in 
a group of 44 patients treated by lopinavir/ritonavir, ribavirin and corticosteroids [64], 
and 0% for 9 patients treated with interferon alfacon-1 and corticosteroids [65].  Only 1 
patient received convalescent plasma as rescue therapy [67].  
 
Of the 152 SARS patients in our cohort, their clinical presentation, virological tests 
results, and treatment regimens have been previously reported [8, 10, 16].  The virus load 
of their nasopharyngeal, serum, stool, and urine specimens collected between day 10 and 
 8
Cheng et al 
15 after onset of symptoms are tabulated in table 3.  There was no significant relationship 
between virus load, age, and the presence of co-morbidities.  However, significant 
decreases in virus load were observed when lopinavir/ritonavir was added to ribavirin 
(table 3).   It is also interesting to note that stool virus load is significantly higher in males 
(7.0 vs 5.5 log10 copies/ml, p=0.02), whereas that of the urine is significantly higher in 
females (1.6 vs 0.6 log10 copies/ml, p=0.01).  Of the 111 (73%) historical controls treated 
with ribavirin and corticosteroids, 12 randomly selected patients had serial virus load 
studies performed on their nasopharyngeal specimens; their mean virus loads were 5.2, 
7.3, 4.9, and 3.8 log10 copies/ml at day 5, 10, 15, and 20 after onset of symptoms 
respectively (figure 1). The decline in virus load in nasopharyngeal specimens coincided 
with the appearance of IgG antibody titers against SARS-CoV during the course of 
infection (figure 2).  Since similar clinical studies of other respiratory viral pneumonias 
were not available in the literature except for a naturally occurring case of influenza [73], 
another 12 cases of experimental infection with RSV by artificial inoculation into healthy 
volunteers were adopted for comparison (figure 2) [74].  The virus load of influenza A 
and RSV peaked at day 2 and 3 respectively, whereas that of SARS-CoV occurred at day 
10 after onset of symptoms (figure 1).  As for the antibody response, baseline antibodies 
of influenza A and RSV were detectable in serum and nasal washings but antibodies 
against SARS-CoV were not present until day 10 after symptom onset. 
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Discussion 
Despite exhaustive laboratory investigations, an etiological agent could be identified in 
only around half of the patients suffering from acute community acquired pneumonia 
[75].  In immunocompetent adults with community acquired pneumonia, pyogenic 
bacteria still constitute the majority of microbiologically documented agents in 
prospective studies [76, 77].    The lack of readily available rapid diagnostic tests for 
respiratory viral infections is one of the major reasons for the lack of reports on the 
natural history, pathogenesis, and treatment of viral pneumonia.  Well-documented 
treatment regimens by randomized control trials are only available for HIV, HCV, HBV, 
HSV, VZV, CMV, and human influenza without pneumonia [78-93].  Moreover, in-vitro 
susceptibility of viruses may not correlate with clinical efficacy, as in the case of 
interferon-alpha used for the treatment of genital herpes [94].  No improvement in 
symptoms score or duration of genital lesions was found irrespective of whether systemic 
or topical interferon-alpha was used [95].  In the case of acute RSV bronchiolitis, the 
efficacy of aerosolized ribavirin was also questionable [96, 97].   
 
Due to the lack of effective antiviral therapy for viral pneumonia, alternative strategies 
using immunomodulation were proposed as early as the 1970s [21].  This was not 
unexpected, since the cytotoxic T cell response may lead to immunopathological damage 
after an initial period of host damage mediated by virus induced cytolysis.  The present 
literature review suggests that at least in the case of human influenza A and hantavirus 
pneumonia, steroid therapy alone may improve the outcome [20-22, 52, 53].  In the case 
of VZV pneumonia, the absence of mortality in cases treated with the addition of steroid 
 10
Cheng et al 
to an efficacious antiviral agent such as acyclovir seems to support such an approach [28, 
29, 39-41].  Despite some decrease in mortality in patients (47.7% vs 63.4%), ribavirin is 
not considered as an effective antiviral for hantavirus [51-55].  However, the use of 
steroids during the phase of severe acute respiratory distress syndrome of hantavirus 
pulmonary syndrome may be associated with reduction in mortality (13.3% vs 63.4%) 
[52, 53].  As emphasized by a group reporting on a cluster of adenoviral pneumonia, the 
use of high dose steroids without an effective antiviral may actually increase mortality 
[47].  However the number of adenoviral pneumonia treated by steroids is too small to 
justify such a conclusion. Overall, the dosage and duration of steroid therapy for viral 
pneumonia were extremely heterogenous, future randomized clinical studies should be 
conducted to ascertain the dosage and duration of steroids associated with the least 
complication which includes secondary infection and avascular necrosis of bone. 
 
Another difficulty in the management of viral pneumonia is the early peaking of the virus 
load which leaves a narrow window of opportunity for antiviral treatment [73, 74].  In 
both human influenza A and RSV, the virus loads peaked at around 2 to 3 days after 
symptom onset in natural and experimental infections of healthy adults (figure 1) [73, 
74].  The early control of virus load in these two infections may be explained by the brisk 
antibody response, possibly due to previous antigenic exposure (figure 2) [73, 74].  A 
completely different picture emerges in the case of SARS.  The virus load in SARS 
patients peaked at around day 10 with a very large area under the curve when compared 
with those of human influenza A and RSV (figure 1).  The onset of antibody response 
was also delayed and started to appear at around day 10.  The failure of innate immunity 
 11
Cheng et al 
and the relatively delayed onset of adaptive antibody response to control virus replication 
may be the explanations for the high mortality of this infection.  Our previous studies 
showed that mortality is directly related to the virus load in nasopharyngeal specimens on 
admission and at day 10 [16, 98].  The mortality was also correlated with the number of 
RT-PCR positive specimens from different body sites including nasopharyngeal, serum, 
stool, or urine [98].  Therefore, an effective antiviral which could reduce the peak virus 
load and area under the curve is the key to the successful treatment of SARS and perhaps 
avian influenza A H5N1, since the general population has no immunological memory 
towards these two viruses.     
 
Intravenous ribavirin was empirically used as a broad-spectrum antiviral agent at the 
beginning of the SARS epidemic in many countries [3-5, 8, 59-63, 66].  Ribavirin was 
selected as it has broad-spectrum antiviral activities possibly through the interference of 
cellular inosine monophosphate dehydrogenase [99].  It has been shown to be effective 
against mouse coronavirus in the setting of fulminant murine hepatitis [100].  Although 
the in-vitro antiviral activity of ribavirin is weak, it has an indirect immunomodulatory 
activity by decreasing the release of proinflammatory cytokines from macrophages of 
mice.  It may also switch the immune response of mice from a T-helper-2 to a T-helper-1 
response [100], which is beneficial for most intracellular infection.  Subsequently in-vitro 
susceptibility testing suggests that antiviral effect could only be achieved at a very high 
concentration which is difficult to achieve clinically [101], despite the fact that ribavirin 
is known to be concentrated in some cell lines such as African green monkey kidney 
(Vero 76) and mouse 3T3 cells [102].  Moreover, the use of high dose regimens indicated 
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for the treatment of hemorrhagic fever was associated with significant hemolysis [12, 72]. 
Thus other options were diligently searched during the epidemic.  Lopinavir/ritonavir was 
then used in addition to ribavirin because of a weak in-vitro antiviral activity on the 
prototype SARS-CoV [10].  The checkerboard assay demonstrated synergisim between 
lopinavir and ribavirin at a low viral inoculum [10].  Other reports suggested that 
glycyrrhizin, interferon beta (Betaferon), interferon alpha n-1 (Wellferon), interferon 
alpha n-3 (Alferon), leucocytic interferon alpha, and baicalin may also have in-vitro 
activity [101, 103-105].  However, interferons were not considered by most clinicians 
during the epidemic because of their known proinflammatory activity, which may 
potentiate the inflammatory damage initiated by the viral infection, and the reported side 
effects of interstitial pneumonitis and bronchiolitis obliterans organizing pneumonia 
[106].  Subsequently pegylated recombinant interferon alpha 2b was shown to be 
effective as pre-exposure and perhaps very early post-exposure prophylaxis in 
cynomolgus macaques (Macaca fascicularis) experimentally infected with SARS-CoV 
[107].  Though different preparations of interferons appeared to be effective in-vitro, only 
recombinant interferon alpha and interferon alfacon-1 has been used in SARS patients 
[61, 65].  Moreover it is still early to say which interferon is likely to be effective in 
human trial because contradictory reports on the in-vitro susceptibility tests were reported 
for interferon beta 1a [101, 108] and interferon alpha 2b [101, 109].  
 
This review has reviewed the anecdotal reports on the treatment of viral pneumonia. The 
findings may be biased since positive results are more likely to be reported.  Steroids 
appeared to confer some benefit in patients with ARDS due to hantavirus, human 
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influenza and VZV.  However, the early use of high dose steroids may be 
counterproductive in the absence of an effective antiviral agent.  Randomized placebo 
controlled trials utilizing different regimens of antivirals with or without steroids should 
be considered for the treatment of SARS and other viral pneumonias in the future. 
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Table 1.  Summary of literature reported cases in the medical management of viral pneumonia other than SARS in immunocompetent host 
Antiviral therapies and / or immunomodulating agents with respect to different viral pathogens;  
sex & age (if mentioned) 
 
Number of 
cases 
Mechanical 
ventilation (%) 
Mortality (%) Reference 
Human influenza A pneumonia – 8 M / 8 F; median age 65 years (23-80 years) 38 24 (63.2) 12 (31.6%) 17-23 
Conservative treatment 19 12 (63.2%) 8 (42.1%) 17-20 
Antiviral alone: Rimantadine (1), oseltamivir (5), combination of oseltamivir & rimantadine (5) 11 8 (72.7%) 3 (27.3%) 20-23 
Corticosteroid alone: MP 500 mg ivi q6h (1); hydrocortisone 250 mg ivi q4h and tailing from day 6 to day 26 
after admission (1) 
8 4 (50%) 1 (12.5%) 20-22 
     
Avian influenza A H5N1 pneumonia - 6 M / 6 F; median age of 24.5 years (16-60 years) 12 6 (50%) 8 (66.7%) 6,7,24,25 
Conservative treatment 2 0 (0%) 1 (50%) 24 
Antiviral alone: Amantadine (4), oseltamivir (3) 7 3 (42.9%) 5 (71.4%) 6,24,25 
Antiviral & immunomodulators: Amantadine for 3 days & steroid in 1; oseltamivir for 5 days & MP 1-2 mg/kg 
ivi q6h for 3 and 4 days in 2 patients respectively 
3 3 (100%) 2 (66.7%) 6,7 
     
VZV pneumonia  - 61 M / 28 F; median age of 31 years (22-88 years) 120 37 (30.8%) 11 (9.2%) 26-43 
Conservative treatment 33 2 (6.1%) 4 (12.1%) 26-29 
Antiviral alone: Intravenous acyclovir (66), vidarabine (2) 68 26 (38.2%) 7 (10.3%) 27-38 
Antiviral & immunomodulators: Intravenous acyclovir & corticosteroid (17), intravenous acyclovir & IVIG (2) 
(hydrocortisone 200 mg ivi q6h for 2 days in 6; hydrocortisone 100 mg ivi q6h and tailing over 1 month in 1; P 
60 mg po qd and tailing over 32 weeks in 1; MP 60 mg ivi q6h for 2 days in 1 patient) 
19 9 (47.4%) 0 (0%) 28,29,39-43 
     
Adenoviral pneumonia -7 M / 3 F; median age of 22 years (18-48 years) 29 12 (41.4%) 6 (20.7%) 21,44-50 
Conservative treatment 25 10 (34.5%) 4 (16%) 44-48 
Corticosteroid alone 4 2 (50%) 2 (50%) 21,44,49,50 
     
Hantavirus pulmonary syndrome - 30 M / 11 F; median age of 33 years (15-63 years) 100 25/56 (44.6%) 49 (49%) 51-55 
Conservative treatment 41 18/26 (69.2%) 26 (63.4%) 51-53 
Antiviral alone: intravenous ribavirin 44 NM 21 (47.7%) 51,54,55* 
Corticosteroid alone 15 7 (46.7%) 2 (13.3%) 52,53 
     
RSV pneumonia - F / 64; aerosolized ribavirin 6 gm 22 hours daily for 5 days 1 1 (100%) 0 56 
     
Measles pneumonia - F / 29; MP 1 gm ivi daily for 2 days and tailing dose thereafter; vitamin A 200,000U orally 
for 2 days 
1 1 (100%) 0 57 
     
EBV pneumonia - M / 30; P 100 mg po daily for 11 days then tailing gradually 1 1 (100%) 0 58 
     
Note.  EBV, Epstein-Barr virus; MP, methylprednisolone; NM, not mention; P, prednisolone; ivi, intravenously; IVIG, intravenous immunoglobulin; RSV, respiratory syncytial 
virus; VZV, varicella-zoster virus; * patients described in reference 55 were also reported in reference 54.
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Table 2.  Summary of literature reported cases in the medical management of SARS in adult 
 
Antiviral therapies and / or immunomodulating 
agents, in addition to empirical broad spectrum 
antibiotics therapy  
 
 
Number 
of cases 
 
 
Sex 
(M:F) 
 
Non-invasive 
ventilation (%) 
 
Mechanical 
ventilation (%) 
 
Pulse MP for clinical 
deterioration (%) 
 
Mortality 
(%) 
 
Reference 
Conservative supportive treatment  13 7:6 0 4 (30.8%) 0 2 (15.4%) 3,5,59,60,68-71
        
Initial medical management (n=772)        
Ribavirin with or without oseltamivir  47 19:28 10 (21.3%) 6 (12.8%) 0 3 (6.4%) 3 
        
Ribavirin & corticosteroid  611 263:348 4 (0.7%) 104 (17%) 54 / 95 (56.8%) 47 (7.7%) 4,5,8,59-63 
        
Ribavirin & high dose pulse MP  17 7:10 0 1 (5.9%) 4 (23.5%) 1 (5.9%) 63 
        
Lopinavir/ritonavir, ribavirin  & corticosteroid  44 12:32 0 0 12 (27.3%) 1 (2.3%) 10*,64 
        
Corticosteroid  14 3:11 0 3 (21.4%) 2 (14.3%) 1 (7.1%) 65,68 
        
Interferon alfacon-1 & corticosteroid  9 3:6 0 1 (11.1%) 5 (55.6%) 0 65 
        
Recombinant interferon alpha 30 11:19 8 (26.7%) 2 (6.7%) 0 2 (6.7%) 61 
        
Rescue medical treatment (n=64)        
Ribavirin or oseltamivir  20 5:15 0 6 (30%) 0 3 (15%) 66 
        
Ribavirin & corticosteroid  12 6:6 0 12 (100%) NM 1 (8.3%) 5 
        
Convalescent plasma  1  F 0 0 1 (100%) 0 67 
        
Lopinavir/ritonavir  31 13:18 0 3 (9.7%) 31 (100%) 4 (12.9%) 64 
        
Note. MP, methylprednisolone; SARS, severe acute respiratory syndrome; SARS-CoV, SARS associated coronavirus.  * 12 patients reported in reference 10 
were included in reference 64.   
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Table 3.  Correlation of demographic data, treatment intervention, and quantitative RT-PCR of clinical specimens between day 10 and 15 in 152 patients with 
SARS  
 
Demographic data  
& treatment intervention 
 
Nasopharyngeal specimens 
(n = 152) 
 
Mean (SD) virus load 
(log10 copies / ml) 
 
 
Serum 
(n = 53) 
 
Mean (SD) virus load 
(log10 copies / ml) 
 
 
Stool 
(n = 94) 
 
Mean (SD) virus load 
(log10 copies / ml) 
 
 
Urine 
(n = 111) 
 
Mean (SD) virus load 
(log10 copies / ml) 
 
Age     
Age equal or more than 60 years  (n=20) 2.5 (3.0) 1.2 (1.3) 6.7 (3.4) 1.4 (2.3) 
Age less than 60 years (n=132) 2.3 (3.1) 1.1 (1.5) 6.0 (3.0) 1.3 (2.1) 
P value 0.83 0.96 0.46 0.84 
     
Sex     
Male (n=58) 2.9 (3.3) 1.4 (1.4) 7.0 (2.6) 0.6 (1.6) 
Female (n=94) 2.0 (2.9) 1.0 (1.4) 5.5 (3.2) 1.6 (2.3) 
P value 0.11 0.44 0.02 0.01 
     
Co-morbidity     
Presence of co-morbidity (n=28) 2.9 (3.3) 1.1 (1.7) 5.9 (3.4) 1.2 (2.1) 
Absence of co-morbidity (n=124) 2.2 (3.0) 1.1 (1.4) 6.1 (3.0) 1.3 (2.1) 
P value 0.31 0.89 0.78 0.79 
     
Lopinavir/ritonavir therapy in addition to ribavirin     
Presence of lopinavir/ritonavir therapy (n=41) 1.3 (2.6) 0.4 (0.9) 4.3 (3.3) 0.5 (1.4) 
Absence of lopinavir/ritonavir therapy (n=111) 2.8 (3.1) 1.4 (1.5) 6.9 (2.6) 1.7 (2.3) 
P value <0.01 0.04 <0.01 <0.01 
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Figure legend 
 
Figure 1.  Sequential quantitative measurements of viral shedding from upper respiratory 
tract during infections with influenza virus, respiratory syncytial virus (RSV), and SARS 
coronavirus (SARS-CoV). Influenza virus quantitation was performed on throat washings 
from a naturally occurring case of influenza in a 28-year-old male. Influenza A / Victoria 
H3N2 virus was isolated using cell cultures [73]. RSV quantitation was done on nasal 
washings from 12 subjects inoculated nasally with 104.7 TCID50 (50 median tissue culture 
infectious dose) RSV A2 challenge pool of virus, developed by the National Institute of 
Allergy and Infectious Diseases.  RSV virus load was measured by quantitative RT-PCR 
using primers based on the nucleotide sequences from the F gene of RSV group A and B 
viruses [74]. SARS-CoV quantitation was performed on nasopharyngeal specimens from 
infected patients. SARS-CoV virus load of 12 patients are measured by quantitative RT-
PCR of Pol gene from nasopharyngeal specimens. 
 
 
Figure 2.  Changing titers of serum antibody of influenza A, nasal IgA of RSV, and IgG 
of SARS-CoV after onset of symptoms. Serum antibody titer (HAI) of influenza A was 
determined using serial sera from a patient who was naturally infected with influenza A 
virus (same patient as shown in Figure 1). Mean RSV nasal IgA titers were obtained from 
nasal washings of 12 subjects who were inoculated with RSV (same group of patients as 
shown in Figure 1). Mean IgG titers of SARS-CoV were obtained using sera from 12 
patients who were infected with SARS-CoV (same group of patients as shown in Figure 
1). 
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Figure 1.  
 
Sequential virus load in patients infected with Influenza A, RSV, and SARS-CoV
0
1
2
3
4
5
6
7
8
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Time after onset of symptoms, days
L
o
g
1
0
 
v
i
r
u
s
 
l
o
a
d
 
(
R
S
V
 
&
 
S
A
R
S
-
C
o
V
)
0
1
2
3
4
5
6
T
C
I
D
5
0
 
t
i
t
e
r
 
(
I
n
f
l
u
e
n
z
a
 
A
)
RSV SARS-CoV Influenza A
 
 31
Cheng et al 
Figure 2. 
 
Sequential antibody level in patients infected with Influenza A, RSV, and SARS-CoV
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